Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.
The partnership will investigate Helicons as standalone therapies and as components of AHCs for potential new therapies. Credit: Gorodenkoff / Shutterstock.com.
Regeneron Pharmaceuticals has signed a $2.32bn research collaboration with Parabilis Medicines to develop therapeutic candidates leveraging the latter’s Helicon peptide platform, with an emphasis on antibody-Helicon conjugates (AHCs).
Helicons are stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets, including those with flat surfaces unsuitable for traditional small molecule engagement. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
